Rampart Bioscience develops gene medicines to provide long-lasting treatments for a wide range of diseases.
Rampart Bioscience has raised $85.0M in total funding. The most recent round was Series A. The last funding was announced in October 2023.
Rampart Bioscience's investors include OrbiMed, RA Capital Management, HealthCap, Forbion Capital Partners.
Rampart Bioscience is headquartered in La Jolla, United States.
Rampart Bioscience develops gene medicines to provide long-lasting treatments for a wide range of diseases.
Rampart Bioscience is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Rampart Bioscience — Funding & Investors." VCBacked, October 24, 2023, https://www.vcbacked.co/company/rampart-bioscience. Accessed July 19, 2026.
VCBacked. (2023). Rampart Bioscience — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/rampart-bioscience
{{cite web |title=Rampart Bioscience — Funding & Investors |url=https://www.vcbacked.co/company/rampart-bioscience |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated